CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Anti-COVID-19 human immunoglobulinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2559 Sampling of tissue Wiki 1.00
drug2674 Standard (specific) therapy for COVID-19 Wiki 1.00
drug556 COVID-19 convalescent plasma Wiki 0.50

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.

NCT04395170 Coronavirus Disease 2019 (COVID-19) Biological: COVID-19 convalescent plasma Biological: Anti-COVID-19 human immunoglobulin Drug: Standard (specific) therapy for COVID-19
MeSH:Coronavirus Infections

Primary Outcomes

Description: Admission to the intensive care unit with the requirement of mechanical ventilation (invasive or non-invasive) due to Acute Respiratory Distress Syndrome by COVID-19.

Measure: Admission to ICU and/or mechanical ventilation

Time: One year

Secondary Outcomes

Description: Time in the hospital from admission to discharge or death.

Measure: Length of hospital stay

Time: One year

Description: Neutralizing antibody (IgG) titers against COVID-19

Measure: Neutralizing antibody (IgG) titers against COVID-19

Time: One year

Description: Non-serious adverse events (NSAEs) and serious adverse events (SAEs)

Measure: Safety - Adverse events

Time: One year

Description: Overall mortality

Measure: Death

Time: One year


No related HPO nodes (Using clinical trials)